IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4778
Positioning
Market Dominance
Manufacturing
Medical Equipment
$16M
Mark White
We design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We developed an easy-to-administer medical device — referred to as Generation 1 or Gen-1 — that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. We were originally formed as a Nevada corporation on October 19, 2010 as Nexalin Technology, Inc. On December 1, 2021, we completed the corporate reorganization pursuant to which Nexalin Nevada merged with and into a newly incorporated Delaware company of the same name, Nexalin and, as a result, Nexalin succeeded Nexalin Nevada and our existing shareholders exchanged each of their shares in Nexalin Nevada for one twentieth (1/20th) of a common share of the newly formed Delaware corporation. Nexalin had nominal assets and liabilities and did not conduct any operations prior to the reorganization other than its incorporation. Our principal executive offices are located at 1776 Yorktown, Suite 550, Houston, Texas.
Headcount
3
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NXL Nexalin Technology, Inc. | 25 | 28 | 20 | 5 | - | - | -173.9% | -161.8% | 69.4% | -6771.6% | -6606.2% | -32.4% | 0.0% | 7.0x | $16M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Nexalin Technology, Inc. (NXL) receives a "Avoid" rating with a composite score of 24.8/100. It ranks #4778 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Mark White
Chief Executive Officer
Labor Force
3
28
35
14
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NXL
HQ Base
Pending Verification
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NXL.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -173.9% (sector -2.5%)
GM 69% vs sector 43%, OM -6772% vs sector 1%
Capital turnover N/A, R&D intensity 661.7%
Rev growth -32%, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Nexalin Technology, Inc. with an Avoid rating, assigning a composite score of 24.8/100 and 1 out of 5 stars. Ranked #4778 of 7,333 stocks, NXL falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
NXL's quality score of 28/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -173.9% (sector avg: -2.5%), gross margins of 69.4% (sector avg: 42.5%), net margins of -6606.2% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
NXL registers a value score of just 20/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.96x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Nexalin Technology, Inc.'s investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -32.4% vs. a sector average of 5.9% and a return on assets of -161.8% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Nexalin Technology, Inc. is experiencing notably weak momentum with a score of just 5/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at -32.4% year-over-year, while a beta of 1.92 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
Nexalin Technology, Inc. registers a low stability score of 14/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.92 and a debt-to-equity ratio of 7.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 48/100 for NXL suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include high market sensitivity (beta: 1.92), elevated leverage (D/E: 7.00x), micro-cap liquidity risk. With a $16M market cap (micro-cap), Nexalin Technology, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Nexalin Technology, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4778 of 7,333 overall (35th percentile). Key comparisons include ROE of -173.9% trailing the -2.5% sector median and operating margins of -6771.6% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NXL currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Momentum (5) would have the largest impact on the composite score.
ROE 6913% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 63% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 525028% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Nexalin Technology, Inc. (NXL) as Avoid with a composite score of 24.8/100 at a current price of $0.56. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in investment (35th percentile) and quality (28th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (5th percentile) and stability (14th percentile) tempers our overall conviction. We assign a No Moat rating (35/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Nexalin Technology, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 24.8/100 places it at rank #4778 in our full 7,333-stock universe. At $16M in market capitalization, Nexalin Technology, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -32% combined with momentum at the 5th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 69% (+26.9pp vs sector) narrow to operating margins of -6772% (-6772.9pp vs sector) and net margins of -6606.2%, yielding a gross-to-net conversion rate of -9519%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.56, Nexalin Technology, Inc. is trading at a premium to fundamental value. Our value factor score of 20/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 2.0x, P/S of 56.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 69% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
A conservative balance sheet (7% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 24.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -32% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -6606.2% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a Very High uncertainty rating to Nexalin Technology, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.92), current negative profitability (net margin -6606.2%), below-average price stability (14th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.92); current negative profitability (net margin -6606.2%); below-average price stability (14th percentile); weak quality scores (28th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 14th percentile and quality factor at the 28th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 69% provide a buffer against cost pressures; conservative leverage (7% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Nexalin Technology, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-173.9%), negative profitability, weak asset returns (ROA -161.8%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Nexalin Technology, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Nexalin Technology, Inc. receives a Avoid rating with a composite score of 24.8/100 (rank #4778 of 7,333). Our quantitative framework assigns a No Moat (35/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 21/100.
Our analysis does not support a constructive view on Nexalin Technology, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Nexalin Technology, Inc. a meaningful economic moat, scoring 35/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12.2/20.
The strongest moat sources are margin superiority (12.2/20) and financial resilience (9.3/20). GM 69% vs sector 43%, OM -6772% vs sector 1%. Interest coverage N/A. These pillars form the core of Nexalin Technology, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and growth durability (3.5/20). ROE proxy -173.9% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Nexalin Technology, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 69% providing a solid profitability foundation, declining revenues (-32%) that pressure the earnings outlook. The margin cascade from 69% gross to -6772% operating to -6606.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 28th percentile.
The margin profile shows gross margins of 69%, operating margins of -6772%, net margins of -6606.2%. Return metrics include ROE of -173.9% and ROA of -161.8%. Relative to the Manufacturing sector, gross margins are 26.9 percentage points above the sector median of 43%, and ROE of -173.9% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 7%, revenue growth of -32%. The sector median D/E is 0%, putting Nexalin Technology, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Weak momentum (5th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (28th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed Clinical Data and International Regulatory Approvals HOUSTON, TX, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced continued advancement toward its
Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s diseaseHOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of Deep Intracranial Frequency Stimulation (DIFS™) technology for non-invasive deep brain stimulation, commended the recent series of bipartisan Congressional initiatives expanding federal focus on deep brain neurost
Nuix Ltd (ASX:NXL) reports robust financial performance with significant revenue and EBITDA growth, while addressing challenges in customer retention and regional performance.
Nuix (ASX:NXL) has put a cleaner set of numbers on the table for H1 2026, reporting revenue of A$121.2 million and basic EPS of A$0.033, backed by net income of A$11.1 million. The company has seen revenue move from A$105.2 million in H1 2025 to A$116.3 million in H2 2025 and then to A$121.2 million in H1 2026. EPS has shifted from a loss of A$0.032 in H1 2025 to A$0.0036 in H2 2025 and then to A$0.033 in the latest half, pointing to a much cleaner earnings profile. For investors, the key...
Electro Optic Systems Holdings Ltd (ASX: EOS) and Nuix Ltd (ASX: NXL) are two of four ASX shares rising on Monday...
Above 50MA
37.18%
Net New Highs
+51081